This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Pf Argentum IP Holdings LLC, Pfizer Corporation. Active years: 2022-2023.
Company Filing History:
Years Active: 2022-2023
Title: Innovations by Emma Linderoth
Introduction
Emma Linderoth is a notable inventor based in Toronto, Canada. She has made significant contributions to the field of cancer treatment through her innovative patents. With a total of 2 patents, her work focuses on enhancing the efficacy of cancer therapies.
Latest Patents
One of her latest patents is the "CD47 blockade therapy by HDAC inhibitors." This invention involves treating CD47-disease cells, such as cancer cells, using a combination of a CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRPαFc as the CD47 blockade drug, along with either depsipeptide or romidepsin as the HDAC inhibitor. These combinations are particularly useful for treating blood cancers, including lymphomas, leukemias, and myelomas.
Another significant patent is the "Enhancement of CD47 blockade therapy by proteasome inhibitors." This invention also targets CD47-disease cells, utilizing a combination of a CD47 blockade drug and a proteasome inhibitor. Similar to her previous patent, the anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRPαFc as the CD47 blockade drug, along with bortezomib, ixazomib, or carfilzomib as the proteasome inhibitor. These combinations are beneficial for treating blood cancers, including lymphomas, leukemias, and myelomas.
Career Highlights
Emma has worked with prominent companies in the pharmaceutical industry, including Pfizer Corporation and Pf Argentum IP Holdings LLC. Her experience in these organizations has contributed to her expertise in developing innovative cancer therapies.
Collaborations
Emma has collaborated with notable professionals in her field, including Natasja Nielsen Viller and Robert Adam Uger. These collaborations have further enriched her research and development efforts.
Conclusion
Emma Linderoth is a pioneering inventor whose work in cancer treatment is making a significant impact. Her innovative patents demonstrate her commitment to advancing medical science and improving patient outcomes.